tbuckley/cabot-search huggingface dataset:
Photothermal Therapy: Multifunctional WS<sub>2</sub>@Polyetherimide Nanoplatforms for Imaging Guided Gene‐Photothermal Synergistic Therapy of Cancer (Adv. Healthcare Mater. 21/2016)
Authors: Chunfang Zhang, Yuan Yong, Li Song, Xinghua Dong, Xiao Zhang, Xiangfeng Liu, Zhanjun Gu, Yuliang Zhao, Zhongbo Hu
Journal: Advanced Healthcare Materials (2016)

On page 2776, Xiangfeng Liu, Zhanjun Gu, Yuliang Zhao, and co-workers describe a multifunctional WS2@poly(ethylene imine) (WS2@PEI) nanoplatform fabricated for gene-photothermal synergistic therapy of tumors under mild conditions. The as-prepared WS2@PEI nanoplatform can not only act as an efficient survivin-siRNA carrier for gene therapy but also exhibits remarkable nearinfrared photothermal effects for photothermal therapy.
Characterizing Transcriptional and Epigenetic Signatures Induced By FLT3-ITD Activation
Authors: Barbara Spitzer, Olga A Guryanova, Omar Abdel-Wahab, Nicole Kucine, Mazhar Adli, Jason N. Berman, Soheil Meshinchi, Bradley Bernstein, Raphael Pelossof, Christina Leslie, Ross L. Levine
Journal: Blood (2014)
Old lessons relearnt
Authors: Elizabeth Loder
Journal: BMJ (2016)

In medicine as in history we often have to learn things the hard way. Sometimes we don’t recognise the value of something until it is gone. The 2012 Health and Social Care Act, for example, eliminated strategic health authorities in England. Our editorialists Nick Black and Nicholas Mays point out that only a few years later regional authority is being reintroduced, in the form of sustainability and transformation plans (doi:10.1136/bmj.i6064). The lesson relearnt is that an intermediate level of governance is needed between local and national services. Meanwhile, the advice Black and Mays offer about this change could be given to Donald Trump’s transition team too: “The …
THU0162 Comparable Time To Retreatment with CT-P10 and Innovator Rituximab up To 2 Years in Patients with Active Rheumatoid Arthritis
Authors: W. Park, D.H. Yoo, C.H. Suh, S.C. Shim, S.J. Lee, S.Y. Lee, T.S. Kwon, S.M. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A randomised controlled trial (RCT) and its open label extension trial (OLE) demonstrated comparable pharmacokinetics (PK), efficacy and safety between CT-P10 and innovator rituximab (RTX) (including switched from RTX to CT-P10) up to 2 years in rheumatoid arthritis (RA) patients (NCT01534884 and NCT01873443).<sup>1,2</sup> <h3>Objectives</h3> To compare time to retreatment and confirm clinical similarity in efficacy and safety by the number of treatment courses in the RCT between CT-P10 and RTX in RA patients up to 2 years. <h3>Methods</h3> One hundred fifty three patients were randomised in 2:1 ratio and received up to 2 treatment courses of either CT-P10 or RTX in RCT, and they had a chance to receive up to 2 additional courses of CT-P10 in OLE. Retreatments were given based on disease activity. Post-hoc analyses using combined data obtained from the RCT and OLE studies were performed in 2 different groups according to the number of treatment courses in RCT as following; Group 1: patients who received 2 courses in RCT; Group 2: patients who received 1 course in RCT. <h3>Results</h3> A total of 82 patients (59 received CT-P10 and 23 received RTX) were in Group 1 and 20 (13 received CT-P10 and 7 received RTX) were in Group 2. Time to retreatment was similar between CT-P10 and RTX (including switched to CT-P10) in each group (Figure 1). DAS28 improvement at Week 24 of each course was similar between CT-P10 and RTX (including switched to CT-P10) in both groups (Table 1). Infusion related reactions by treatment course up to 2 years was similar between the CT-P10 and RTX groups and tended to decrease over time in line with RTX historical data.<sup>3</sup> Incidence rate of adverse event, serious adverse event and infection was comparable between CT-P10 and RTX groups. <h3>Conclusions</h3> The results of the post-hoc analyses demonstrated comparable duration of disease control between CT-P10 and RTX (including switched to CT-P10) with clinical similarity in efficacy for 2 years. The safety profile of CT-P10 was similar to that of RTX and in line with RTX historical data. <h3>References</h3> Yoo DH, et al. Arthritis Rheum 2013; 65 (Suppl10): S736 Yoo DH, et al. Arthritis Rheum 2015; 67 (Suppl10): 2449–245 van Vollenhoven RF, et al. EULAR 2013 (Madrid, Spain): Poster SAT0131 <h3>Disclosure of Interest</h3> W. Park Consultant for: CELLTRION,INC., D. H. Yoo Consultant for: CELLTRION,INC., C. H. Suh Consultant for: CELLTRION,INC., S. C. Shim Consultant for: CELLTRION,INC., S. J. Lee Employee of: CELLTRION,INC., S. Y. Lee Employee of: CELLTRION,INC., T. S. Kwon Employee of: CELLTRION,INC., S. M. Kim Employee of: CELLTRION,INC.
AB0360 Impact of Abatacept on Disease Activity and Functional Status in Patients with Different Duration of Rheumatoid Arthritis
Authors: M.A. Kanonirova, G. Lukina, Y. Sigidin, E. Aronova, S. Glukhova, E. Luchihina, D. Karateev, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Abatacept (ABA) is a selective co-stimulation modulator, which is widely used in treatment of RA. There isn9t enough data about its effectiveness and impact on functional status in patients with early (ERA) and long-standing (LS) rheumatoid arthritis (RA). <h3>Objectives</h3> To assess the impact of ABA on disease activity and functional status in patients with different duration of RA. <h3>Methods</h3> 85 patients (pts) with active RA and an inadequate response to synthetic DMARDs or biologics were enrolled in the study. They were grouped into 2 arms based on RA duration: less than three years (early RA) and more than three years (LS RA), i.e. 51% and 49% pts in each group, respectively. Most of them were middle aged females (48,8±13,5 years) with high disease activity (DAS28=5,25±1,15), RF-positive (76,7%) and ACPA-positive (73,1%). ABA (10 mg/kg) was administered intravenously following the adult intravenous dosing regimen. Disease activity was assessed by DAS28, functional status by HAQ-DI and results by EULAR criteria every 12 weeks. <h3>Results</h3> Before treatment DAS28 in ERA pts was 5,1±0,9, in LS RA – 5,3±1,3 and HAQ-DI in ERA pts was 1,3±0,6, in LS RA - 1,6±0,9. In three months after ABA therapy initiation a significant improvement in DAS28 and HAQ-DI was achieved in both groups (<i>p</i>&lt;0,05). Improvement by EULAR response criteria was registered in 80% of pts with ERA and 67% of pts with LS RA. There was no significant difference between two groups after 3 and 6 months of treatment in achieving a good EULAR response: 27,5% and 43,75% – in early RA pts, 28,57% and 38,4% – in LS RA pts. There was a comparable percentage of non-responders after 3 and 6 months of therapy in both groups (at 3 months – 20% in early RA group, 31,4% – in LS RA group; at 6 months – 18,7% and 19,2% respectively). After 3 months and 6 months the improvement of HAQ-DI in ERA group was significantly higher, than in LS RA group (p&lt;0.05). 28 adverse events (AEs) in 17 (20%) pts were registered. The most frequent AE were upper respiratory tract infections – 10 (11,8%) pts. Serious AEs (SAEs) occurred in 4 (4,7%) pts. <h3>Conclusions</h3> ABA has shown significant improvement in reduction of disease activity and improvement in functional status in pts with RA. No significant difference was seen between the groups of ERA and LS RA by EULAR criteria. However, pts in ERA group had significant improvement of HAQ-DI comparing with LS RA group. ABA has good safety profile, adverse events were registered only in 20% of patients. <h3>Disclosure of Interest</h3> None declared
Kinetics of Autologous Stem Cell Mobilization Failure: Comparison of AMD3100/G-CSF, G-CSF, GM-/G-CSF, and Chemotherapy/G-CSF on Remobilization Success.
Authors: John F. DiPersio, Angela Smith, Dianne Sempek, Albert Baker, Steven Jiang, Ravi Vij, Amanda Cashen, Peter Westervelt
Journal: Blood (2006)
High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.
Authors: Liliana Devizzi, Ettore Seregni, Anna Guidetti, Chiara Forni, Angela Coliva, Michele Magni, Massimo Di Nicola, Carmelo Carlo-Stella, Paola Matteucci, Antonella De Pascale, Claudia Erminero, Marco Maccauro, Carlo Chiesa, Emilio Bombardieri, Pinuccia Valagussa, Alessandro M. Gianni
Journal: Blood (2006)
SAT0476 Efficacy of 14% Plai vs. Placebo Creams for Symptomatic Control of Patients with Knee Osteoarthritis
Authors: W. Kosuwon, W. Sirichativapee, T. Wisanuyotin, P. Paholpak, P. Laupattarakasem
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Non-operative treatments for mild to moderate knee osteoarthritic (OA) is recommended. Plai (Zingibercassumunar Roxb.) belongs to the ginger family. It is a Thai herb used in Thai traditional medicine for relieving muscle and joint pain (1–2). Plai has anti-inflammatory activities due to compounds found in its extracts (1–4). These findings suggest that topical plai cream is a potentially useful drug for the treatment of painful OA of the joints. Since there have not been any studies on the efficacy of plai cream alone for relieving symptoms of OA knee joint, we aimed to test its value. <h3>Objectives</h3> To assess the efficacy of topical plai cream for the treatment of primary osteoarthritis (OA) knee. <h3>Methods</h3> This was a 9-week (4 weeks treatment + 1 week wash-out + 4 weeks placebo) phase III randomized, double-blind, controlled, cross-over, community trial of Plai vs. placebo, in adults with OA of the knee. This study aimed to determine whether Plai cream was more effective at reducing pain than a placebo cream, as measured using a visual analog scale (VAS) plus the Western Ontario McMaster (WOMAC) score. <h3>Results</h3> A total of 120 pairs of subjects were enrolled. The mean different VAS favoring Plai varied between 0.46 and 1.4 (p&lt;0.05). The respective percentage of patients in the Plai group who reached MCII of VAS, WOMAC pain, stiffness and function was 37.9%, 40.10%, 26.45% and 54.58%. The respective percentage of patients in the Plai group who experienced 50% improvement of VAS, WOMAC pain, stiffness and function was 33.33%, 31.77%, 41.66% and 24.68%. The respective number of cases needed to treat to reduce pain of Plai based on MCII and 50% improvement of VAS was 2.63 (95% CI; 2.44, 2.84) and 3 (95% CI; 2.75, 3.29). Four cases in the Plai group had a mild skin reaction. <h3>Conclusions</h3> This cross-over, randomized, controlled, communit, trial demonstrated that Plai cream is an effective topical agent for relieving the symptoms of mild to moderate OA knee. <h3>References</h3> Panthong A, Kanjanaponthi D, Niwatananun V, Tuntiwachwuttikul P, Reutrakul V. Anti-inflammatory activity of compounds isolated from Zingiber cassumunar. Planta Med. 1990;56:655. Han AR, Kim MS, Jeong YH, Lee SK, Seo EK. Cyclooxygenase-2 inhibitory phenylbutenoids from the rhizomes of Zingiber cassumunar. Chem Pharm Bull (Tokyo). 2005;53(11):1466–8. Chaiwongsa R OS, Tangyuenyong S, Kongtawelert P, Panthong A, Reutrakul V. Chondroprotective potential of bioactive compounds of Zingiber cassumunar Roxb. Against cytokine-induced cartilage degeneration in explant culture. J Med Plants Res. 2012;6 (39):5204–13. Leelarungravub D SM. Potential antioxidant and anti-inflammatory activity of Thai plai (Zingiber cassumunar Roxb.) essential oil. International Journal of Essential Oil Therapeutics. 2009;3(1):25–30. <h3>Disclosure of Interest</h3> None declared
Favourable Outcome of B-Cell Non Hodgkin Lymphomas Associated with Hepatitis C Virus - ANRS HC13 LYMPHO-C Observational Study
Authors: Caroline Besson, Danielle Canioni, Catherine Settegrana, Henda Driss, Laurent Alric, Cyrille Feray, Felipe Suarez, Florence N Guyen Khac, Helene Merle-Beral, Patrice Cacoub, Frederic Davi, Olivier Hermine
Journal: Blood (2010)
Rethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis
Authors: Gregory S. Day
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Risk Factors Analyses for Outcomes after Unrelated Cord Blood Transplantation for Children with Myelodysplastic Syndromes. An Analysis on Behalf of EWOG-MDS and Eurocord Groups.
Authors: Adrienne B. Moreno-Madureira, Pierre Teira, Franco Locatelli, Alessandra Piccardi, Ann Woolfrey, Ka-Wah Chan, Gérard Socié, Ajay J. Vora, Yves Bertrand, Carmem Bonfim, Federico Garnier, Irina Ionescu, Eliane Gluckman, Charlotte M. Niemeyer, Vanderson Rocha
Journal: Blood (2007)
The Role of Activation-Induced Cytidine Deaminase (AID/AICDA) in the Progression of Follicular Lymphoma
Authors: Hisaharu Shikata, Yoshihiro Yakushijin, Natsuki Matsushita, Akira Sakai, Atsuro Sugita, Naoya Nakamura, Jun Yamanouchi, Taichi Azuma, Takaaki Hato, Masaki Yasukawa
Journal: Blood (2011)
Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia: Comparison Between Ethnic Populations in Israel
Authors: Ronit Elhasid, Aya Abramov, Nira Arad -Cohen, Dina Attias, Galia Avrahami, Ami Ballin, Myriam Ben Arush, Bella Bielorai, Yoav Burstein, Sara Elitzur, Hertzel Gavriel, Joseph Kapelushnik, Dalia Sthoeger, Amos Toren, Isaac Yaniv, Michael Wientraub, Ronit Nirel, Shai Izraeli, Batia Stark
Journal: Blood (2014)
The B-Cell Chemoattractant Factor CXCL13 Is Expressed in the Malignant Lymphocyte of the Sezary Syndrome.
Authors: Maria Grazia Narducci, Maria Cristina Picchio, Cristina Lazzeri, Irene Angelucci, Enrico Scala, Antonella Bresin, Elisabetta Caprini, Marina Frontani, Gianluca Ragone, Daniele Remotti, Giuseppe Lombardo, Giannandrea Baliva, Giandomenico Russo
Journal: Blood (2006)
A Novel Chromene-Based Pan-PI3 Kinase Inhibitor Displays Preclinical Activity in Leukemia and Myeloma.
Authors: Xinliang Mao, Tabitha W. Wood, Xiaoming Wang, Johnathan St-Germain, Michael F. Moran, Alessandro Datti, Jeff Wrana, Robert A. Batey, Aaron D. Schimmer
Journal: Blood (2008)
Enzymatic Activity of the Scaffold Protein Rapsyn for Synapse Formation
Authors: Lei Li, Yu Cao, Haitao Wu, Xinchun Ye, Zhihui Zhu, Guanglin Xing, Chengyong Shen, Arnab Barik, Bin Zhang, Xiaoling Xie, Wenbo Zhi, Lin Gan, Huabo Su, Wen-Cheng Xiong, Lin Mei
Journal: Neuron (2016)
Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
Authors: Deborah A. Thomas, Hagop M. Kantarjian, Jeffrey L. Jorgensen, Stefan Faderl, Jorge Cortes, Francis Giles, Guillermo Garcia-Manero, William Wierda, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Charles Asa Koller, Miloslav Beran, Steven M. Kornblau, Michael Andreeff, Dan Jones, Susan O’Brien
Journal: Blood (2006)
PWE-097 3D High Resolution Manometry Verses Standard Water Perfused Ano Rectal Manometry in The Evaluation of Anorectal Disease #393: Abstract PWE-097 Table 1
Authors: D Solanki, K Odedra, A Schizas
Journal: Gut (2016)

<h3>Introduction</h3> The aim of this study was to compare standard 8 channel water perfused catheter to a HARM 28 channel catheter in patients with both evacuatory bowel disorders and faecal incontinence. <h3>Methods</h3> 50 patients referred for WPM testing also underwent simultaneous HRAM testing. WPM was performed using an 8 channel radial arranged catheter using an automated puller to evaluate vector volume pressure profiles of the anal sphincter complex, and also a station pull through technique to further assess pressure profile. Rectal sensory function was evaluated using a separate water perfused catheter. This was compared to a HRAM 28 pressure catheter with 28 circumferential sensors along 6 cm length. A balloon was attached over a rectal sensor which would allow evaluation of rectal pressure change throughout the entire study. Anal canal resting pressure, squeeze pressure, anal canal length, rectal sensations and presence recto-anal inhibitory reflex were recorded using both catheters. Comparison of the anal canal pressures using the water perfused catheter were made to the pressure profile from the HRAM studies. The HRAM also allows for real time pressure measurement of anal canal pressure as a balloon is inflates in the rectum, simulating rectal filling. This in theory give a more physiology sphincter contraction. This was compared to patient symptoms. <h3>Results</h3> 50 patients with either faecal incontinence symptoms and or evcuatory disorders underwent both water perfused manometry and High resolution ano rectal manometry. (24 with evcuatory difficulties/ constipation, 21 with faecal incontinence. The results are summarised in the table below. Analysing the squeezes pressure during balloon distension showed that there was a significant difference between those patients with faecal incontinence (40 mmHg) and constipation (77 mmHg) (p = 0.036). <h3>Conclusion</h3> There is good correlation between the modalities and the HRAM can obtain substantially greater real time physiological information. HRAM with balloon rectal distension appears to be more sensitive in identifying difference between patients with no faecal incontinence and faecal incontinence though further work is required following this preliminary study. <h3>Disclosure of Interest</h3> None Declared
Where Is the Culprit Lesion?
Authors: Antoni Bayés de Luna, Miguel Fiol-Sala
Journal: Circulation (2016)

ECG ChallEnGEA 67-year-old man who had experienced a previous heart attack 6 years ago now presents with severe constrictive chest pain for >2 hours with profuse sweating and low blood pressure.An ECG is recorded (Figure 1), and immediately after, the cardiac catheterization laboratory is activated.No prior ECGs are available.What is the diagnosis and what is the precise anatomic lesion?Please turn the page to read the diagnosis.
L’ESGE définit les questions clés non résolues en endoscopie digestive
Authors: G. Lesur
Journal: Endoscopy (2016)

Une des missions de l’ESGE est de faire avancer les connaissances en endoscopie digestive et de réfléchir à l’avenir de la spécialité. L’ESGE avait ainsi décidé de faire une enquête auprès de ses membres sur ce qui leur semblait le plus susceptible de devoir être approfondi dans le domaine de l’endoscopie digestive.
AB0814 Online Patient Information Resources on Gout Provide Inadequate Information and Minimal Emphasis on Potentially Curative Urate Lowering Treatment
Authors: L. Jiménez-Liñán, L. Edwards, A. Abhishek, M. Doherty
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Nowadays patients use the internet to find more about their disease and its management. The accuracy of online gout patient information resources has not been examined before. <h3>Objectives</h3> To assess the content, accuracy and readability of freely available online patient information resources against the current understanding of gout. <h3>Methods</h3> An internet search was carried out to identify online gout patient information resources from the United States of America (USA), United Kingdom (UK), Australia and Canada in October 2015. Websites aimed at healthcare professionals, those requiring a paid subscription, or focussed on a specific aspect of gout were excluded. Information provided in the websites was compared against 15 key points. If information on a key point was regarded as present, it was classified on a 1–3 Likert Scale (1-inaccurate, 2-acceptable information with some inaccuracy and 3-acurate). Readability was assessed using Flesch-Kincaid Reading Ease score. Fifteen randomly selected websites were reviewed by a binder second reviewer. <h3>Results</h3> Eighty-five websites (30 provided by a medical and/or healthcare organisation were selected). Information was provided for a mean (SD) 7.73 (2.85) of 15 key points overall. The websites were more likely to contain information on risk-factors than on treatment of gout (p&lt;0.001). More than 50% provided no information, or had inaccuracies regarding the pathogenesis of gout and over 75% of websites had no or inaccurate information on the role of ULT. Most websites highlighted information on dietary and lifestyle modifications for treating gout and did not emphasise ULT and its potential for cure. The two raters agreed in 80% of occasions on whether information on a particular question was present or not (<i>k</i> 0.60). The majority of websites were difficult to read, with information in 68% websites rated as at least fairly difficult. <h3>Conclusions</h3> Most of the patient information on gout available online is inaccurate and commonly over emphasises the use of dietary and lifestyle changes as a way of managing gout. The importance of ULT in managing gout and the potential for gout being curable with long-term ULT are not explained well. Moreover, most websites were difficult to read and most on-line resources had inaccuracies regarding the pathogenesis and treatment of gout. <h3>Disclosure of Interest</h3> None declared
Soluble Endothelial Protein C Receptor (sEPCR) Is Increased in Cirrhotic Patients. A Possible Role in Procoagulant Imbalance?
Authors: Thomas Sinegre, Cedric Duron, Ahmed Bouras, Arnaud Serres, Marc G Berger, Anne-Françoise Sapin, Armand Abergel, Aurelien Lebreton
Journal: Blood (2015)
Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd
Authors: Joon Ho Moon, Sang Kyun Sohn, Jieun Uhm, Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, John Kuruvilla, Dennis Dong Hwan Kim
Journal: Blood (2012)